Cancer Immunotherapy Collection (2017-2019)

The collection includes all the papers on cancer immunotherapy published by Cancer Biology & Medicine in 2017-2019

Table of Contents

Editorial

The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role? PDF
Amy L. Cummings, et al. 341-347
Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle PDF
Xiubao Ren 205-210

Review

Cellular immunity augmentation in mainstream oncologic therapy PDF
Daohong Chen, et al. 121-128
New developments in immunotherapy for lymphoma PDF
Benjamin Heyman, et al. 189-209
PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy PDF
Long Jia, et al. 116-123
Current applications and future prospects of nanotechnology in cancer immunotherapy PDF
Sen Yan, et al 486-497
Technical advances in NK cell-based cellular immunotherapy PDF
Fang Fang, et al 647-654
The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy PDF
Wenxiao Jia, et al. 655-670
Low-frequency HIFU induced cancer immunotherapy: tempting challenges and potential opportunities PDF
Guilian Shi, et al. 714-728

Original Article

PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs PDF
Yuchen Bai, et al. 434-442
The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis PDF
Shu Zhao, et al. 290-298
Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients PDF
Yuhan Zhang, et al. 350-360
Human natural killer cells for targeting delivery of gold nanostars and bimodal imaging directed photothermal/photodynamic therapy and immunotherapy PDF
Bin Liu, et al. 756-770
The correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients: a single center case series PDF
Jianghua Wu, et al 811-821


OUR FRIENDS